Comparative Pharmacology
Head-to-head clinical analysis: TZ 3 versus ZURAGARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TZ 3 versus ZURAGARD.
TZ-3 vs ZURAGARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
ZURAGARD (zagociguat) is a soluble guanylate cyclase (sGC) stimulator that enhances the sensitivity of sGC to nitric oxide (NO) and directly stimulates sGC independently of NO, leading to increased cyclic guanosine monophosphate (cGMP) production. This results in vasodilation and improved hemodynamics.
100 mg orally twice daily
16 mg/kg intravenously every 12 hours for 2 days, followed by 8 mg/kg intravenously every 12 hours for 3 days.
None Documented
None Documented
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Terminal elimination half-life is approximately 14-18 hours in healthy adults, allowing once-daily dosing; may be prolonged in renal impairment (up to 40 hours in severe impairment).
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Primarily renal excretion (60-70% as unchanged drug); biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Unknown
Unknown